Partly focused on delivery challenges that have limited the reach of RNA medicines, new biotech company Axelyf Inc. closed a $2.6 million seed round to support development of its AXL technology and to advance lead autoimmune candidate AXL-003. Read More
Bronchopulmonary dysplasia (BPD) is a common morbidity in infants born prematurely and characterized by airway hyperreactivity and adverse neurodevelopmental sequelae in surviving infants; therapeutic options are evasive and glucocorticoids are mostly used during the disease but with limitations. Researchers from Ayuvis Research LLC have recently published results on a Toll-like receptor 4 (TLR4) antagonist, AVR-48, for the potential treatment of BPD. Read More
HCW Biologics Inc. has outlined its development of second-generation, pembrolizumab-based immunotherapeutics against solid tumors, particularly for pancreatic and ovarian cancer, using its proprietary T-cell Receptor β Chain constant region (TRBC) product discovery and development platform technology. Read More
Curasight A/S has received clinical trial approval from the EMA for phase I evaluation of Utreat as a new type of targeted radiopharmaceutical therapy in glioblastoma patients. The trial will enroll participants with newly diagnosed verified or suspected glioblastoma, and dosing is expected to commence in the fourth quarter of this year. Read More
Haisco Pharmaceutical Group Co. Ltd. has identified sulfur-containing heterocyclic derivatives acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain. Read More
Arnatar Therapeutics Inc.’s ART-4, an upregulating antisense oligonucleotide (ASO) therapeutic candidate for the treatment of Alagille syndrome (ALGS), has been awarded U.S. orphan drug and rare pediatric disease designations by the FDA. Approximately 95% of ALGS cases are caused by haploinsufficient mutations in the Jagged-1 (JAG1) gene, leading to insufficient JAG1 protein levels and impaired liver bile duct development. Read More
Heat shock protein family H member 1 (HSPH1) plays a key role in cellular stress and protein homeostasis, and it has been implicated in proliferation, invasion and metastasis of tumor cells. A recent study aimed to investigate the link between HSPH1 and the prognosis of HCC. Read More
Pfizer Inc. has disclosed salts of gastric inhibitory polypeptide receptor (GIPR) antagonists reported to be useful for the treatment of type 2 diabetes and obesity. Read More
Novartis AG has synthesized cyanotrizole compounds reported to be useful for the treatment of leishmaniasis, American trypanosomiasis (Chagas disease) and African trypanosomiasis (sleeping sickness). Read More
Chinese researchers have developed a new a circulating exosomal proteomic biomarker signature that may aid in the diagnosis of interstitial lung disease (ILD) in combination with computed tomography. Exosomes may contribute to lung disorders by carrying cargoes that promote inflammatory responses in immune and lung epithelial cells. The assay was performed in a case-control biomarker study; exosomes from 168 serum samples were extracted and submitted to proteomic analysis. Read More
Technische Universität München has described conjugates comprising a silicone-based fluoride acceptor (SiFA)-based peptide targeting moiety covalently linked to radiolabeled chelating agents through a divalent linker. Read More
Neurogenic bladder is a disease involving inflammation and fibrosis of the bladder. Fibrosis has been linked to the type of programmed cell death known as pyroptosis, which in turn has been linked to cGAS-STING signaling and subsequent activation of the NLRP3 inflammasome. Researchers at Children’s Hospital of Chongqing Medical University wondered whether the same processes contribute to the fibrosis in neurogenic bladder. Read More
